RMTIHealthcare · Drug Manufacturers - Specialty & GenericThe 2 Wall Street analysts covering Rockwell Medical, Inc. hold a median 12-month price target of $20 — +143.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 7 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Rockwell Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RMTI, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +143.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $20 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 11 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | $9.00 |
| 4 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | $9.00 |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Oct 2023 | Maxim Group | Initiates | Buy | — |
| 4 Oct 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Sept 2023 | HC Wainwright& Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RMTI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 84% of US stocks
Cheaper than 75% of US stocks
Cheaper than 83% of US stocks
Higher than 54% of US stocks
Higher than 49% of US stocks
Higher than 19% of US stocks
Higher than 26% of US stocks
Higher than 22% of US stocks
Higher than 33% of US stocks
Higher than 32% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rockwell Medical, Inc. has a market value of $30.8M and an enterprise value of $20.0M.
Revenue in the twelve months to 30 June 2026: $69.4M. The latest quarter grew 10.6% year on year.
Net income over the same four quarters: −$5.1M, a −7.3% net margin.
Diluted earnings per share, trailing twelve months: $−1.34.
Free cash flow in the twelve months to 30 June 2026: $1.5M.
Trailing P/E: −5.2×; forward P/E: 109.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Rockwell Medical, Inc. employs 157 people — $442K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rockwell Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rockwell Medical ranked No. 16 on Fortune’s 2026 Best Workplaces in Manufacturing & Production list. This is the company’s third consecutive year on the list, improving from No. 50 in 2024 and No. 40 in 2025.
Why it matters — The recognition and higher ranking may interest RMTI watchers tracking the company’s workplace reputation.
Rockwell Medical, Inc. held its Q2 2026 earnings conference call, during which management discussed the company's financial results and operational performance for the quarter.
Why it matters — Earnings calls provide investors and analysts with direct insight into the company's financial health, strategic direction, and management's perspective on recent performance.
Rockwell Medical reported a Q2 loss of $0.34 per share, wider than the Zacks Consensus Estimate of a $0.17 loss but narrower than the $0.50 per-share loss from a year ago. The company also lagged revenue estimates for the quarter.
Why it matters — An RMTI watcher would care because the wider-than-expected quarterly loss and revenue miss signal that the company's results fell short of analyst expectations for the period.
Rockwell Medical announced its second quarter 2026 results for Wixom, Michigan, reporting strong year-over-year growth, an expanding gross margin, and positive operating cash flow.
Why it matters — RMTI watchers would care because the quarter reflects strengthening financial performance, including growth, margin expansion, and positive cash flow.
Zacks reports that Rockwell Medical (RMTI) may post negative earnings in its upcoming report, noting the company lacks the combination of key ingredients typically associated with a likely earnings beat. The piece advises investors to prepare for the release by reviewing key expectations.
Why it matters — RMTI investors would care because the item points to a potentially unfavorable earnings outcome ahead of the company's upcoming report.
The 2 Wall Street analysts covering Rockwell Medical, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Rockwell Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rockwell Medical, Inc. 53 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 7 Oct 2026, Rockwell Medical, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +143.3% from the last close, and Ticker Nerd's factor model ranks Rockwell Medical, Inc. 53 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rockwell Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RMTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
Rockwell Medical Inc. is a healthcare company focused on developing, manufacturing, commercializing, and distributing hemodialysis products for dialysis providers worldwide.
The most recent item we track (Business Wire, 7 Oct 2026): "Rockwell Medical Ranked No. 16 on the 2026 Fortune ‘Best Workplaces in Manufacturing & Production' List". Rockwell Medical ranked No. 16 on Fortune’s 2026 Best Workplaces in Manufacturing & Production list. This is the company’s third consecutive year on the list, improving from No. 50 in 2024 and No. 40 in 2025.
Rockwell Medical Inc. is a healthcare company focused on developing, manufacturing, commercializing, and distributing hemodialysis products for dialysis providers worldwide. Its portfolio centers on liquid and dry acid and bicarbonate concentrates, along with related mixers and ancillary supplies used in dialysis treatment. The company serves outpatient dialysis centers, hospital-based facilities, skilled nursing settings, and home care environments, supporting the day-to-day delivery of kidney care. Rockwell Medical’s products are designed to help maintain the dialysis process by removing toxins and balancing electrolytes in patients with end-stage kidney disease. The company operates manufacturing and distribution capabilities that support customers in the United States and international markets, making it an important supplier within the renal care and dialysis supply chain. Headquartered in Wixom, Michigan, Rockwell Medical continues to focus on specialized products and services for the hemodialysis market.
CEO Dr. Mark Strobeck Ph.D. · 157 employees · United States · https://www.rockwellmed.com